Guidelines for Genetic Testing and Management of Alport Syndrome

Area of Science:

• Nephrology
• Genetics
• Molecular Biology

Background:

• Persistent hematuria and kidney function impairment can indicate underlying genetic conditions.
• Alport syndrome and familial FSGS are often linked to variants in the COL4A3-COL4A5 gene cluster.
• Early genetic diagnosis is crucial for risk assessment and management.

Purpose of the Study:

• To highlight the importance of genetic testing for pathogenic COL4A3-5 variants.
• To advocate for expanded genetic testing criteria in nephrology.
• To inform clinical recommendations regarding kidney donation for heterozygotes.

Main Methods:

• Genetic testing for pathogenic variants in COL4A3, COL4A4, and COL4A5 genes.
• Analysis of patient history, including family history of hematuria and kidney function.
• Review of expert recommendations for genetic testing and donor eligibility.

Main Results:

• Genetic testing is recommended for persistent hematuria, especially with a family history or kidney impairment.
• Cascade testing of first-degree relatives is advised for suspected heterozygous pathogenic COL4A3 or COL4A4 variants.
• Testing is also indicated for persistent proteinuria, steroid-resistant nephrotic syndrome, familial IgA glomerulonephritis, and unexplained kidney failure.

Conclusions:

• Genetic testing of COL4A3-5 variants is essential for diagnosing the cause of persistent hematuria and other kidney diseases.
• Experts recommend that individuals with heterozygous pathogenic COL4A3 or COL4A4 variants should not donate kidneys.
• Expanded genetic testing facilitates early diagnosis, risk stratification, and informed clinical decision-making.